Abivax: in green, broker in support
The analyst points out that this financing of up to 150 million euros includes two structured financing transactions, half of which will be arranged with Kreos Capital/Claret European Growth Capital, with the remainder underwritten by Heights Capital Management.
The analyst is also 'convinced by the clinical benefits of obefazimod for UC patients, following the excellent Phase IIb results obtained in the induction and maintenance phase, which partly derisks Phase III'
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction